IRES-Mediated Protein Translation Overcomes Suppression by the p14ARF Tumor Suppressor Protein.


Type
Article
Change log
Authors
Xi, Song 
Zhao, Ming 
Wang, Si 
Ma, Ling 
Wang, Shensen 
Abstract

Internal ribosome entry sites (IRES elements) have attracted interest in cancer gene therapy because they can be used in the design of gene transfer vectors that provide bicistronic co-expression of two transgene products under the control of a single promoter. Unlike cellular translation of most mRNAs, a process that requires a post-translational 5' modification of the mRNA known as the cap structure, IRES-mediated translation is independent of the cap structure. The cellular conditions that may intervene to modulate IRES-mediated, cap-independent versus cap-dependent translation, however, remain poorly understood, although they could be critical to the choice of gene transfer vectors. Here we have compared the effects of the p14ARF (Alternate Reading Frame) tumor suppressor, a translational suppressor frequently overexpressed in cancer, on cap-dependent translation versus cap-independent translation from the EMCV viral IRES often used in bicistronic gene transfer vectors. We find that ectopic overexpression of p14ARF suppresses endogenous and ectopic cap-dependent protein translation, consistent with other studies. However, p14ARF has little or no effect on transgene translation initiated within an IRES element. This suggests that transgenes placed downstream of an IRES element will retain efficient translation of their gene products in the presence of high levels of ectopic or endogenous p14ARF, a finding that could be particularly relevant to therapeutic gene therapy strategies for cancer.

Description
Keywords
Internal ribosome entry site (IRES), cap-dependent, p14ARF, protein translation.
Journal Title
J Cancer
Conference Name
Journal ISSN
1837-9664
1837-9664
Volume Title
8
Publisher
Ivyspring International Publisher
Sponsorship
Cambridge University Hospitals NHS Foundation Trust (CUH) (3819-1516-08)
MRC (unknown)
Medical Research Council (MC_UU_12022/2)